Shares of Arrowhead Research Corp. (NASDAQ:ARWR) rose 5.1% on Tuesday . The company traded as high as $7.47 and last traded at $7.24, with a volume of 770,957 shares. The stock had previously closed at $6.89.

ARWR has been the topic of a number of research reports. Cantor Fitzgerald initiated coverage on shares of Arrowhead Research Corp. in a research note on Wednesday, August 17th. They issued a “buy” rating and a $15.00 price objective on the stock. Chardan Capital initiated coverage on shares of Arrowhead Research Corp. in a research note on Thursday, May 19th. They issued a “buy” rating and a $12.00 price objective on the stock. William Blair initiated coverage on shares of Arrowhead Research Corp. in a research note on Friday, August 19th. They issued an “outperform” rating on the stock. Jefferies Group reiterated a “hold” rating and issued a $4.75 price objective on shares of Arrowhead Research Corp. in a research note on Wednesday, May 11th. Finally, Piper Jaffray Cos. cut their price objective on shares of Arrowhead Research Corp. from $13.00 to $8.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 10th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Arrowhead Research Corp. has a consensus rating of “Buy” and a consensus target price of $10.44.

The company’s 50 day moving average is $6.17 and its 200-day moving average is $5.48. The stock’s market cap is $430.11 million.

Arrowhead Research Corp. (NASDAQ:ARWR) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.05. The firm had revenue of $39.58 million for the quarter, compared to analyst estimates of $0.05 million. The company’s revenue was down 68.0% on a year-over-year basis. During the same quarter last year, the firm earned ($0.27) EPS. Equities research analysts expect that Arrowhead Research Corp. will post ($1.31) EPS for the current year.

In other Arrowhead Research Corp. news, CFO Kenneth Allen Myszkowski sold 6,900 shares of the business’s stock in a transaction that occurred on Tuesday, August 23rd. The shares were sold at an average price of $8.00, for a total transaction of $55,200.00. Following the completion of the transaction, the chief financial officer now owns 128,789 shares in the company, valued at approximately $1,030,312. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, is a biopharmaceutical company. The Company is engaged in developing RiboNucleic Acid interference (RNAi) therapeutics. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA. ARC-520 is designed to treat chronic hepatitis B virus (HBV) infection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.